TW200845991A - N-substituted glycine derivatives: hydroxylase inhibitors - Google Patents

N-substituted glycine derivatives: hydroxylase inhibitors Download PDF

Info

Publication number
TW200845991A
TW200845991A TW097100936A TW97100936A TW200845991A TW 200845991 A TW200845991 A TW 200845991A TW 097100936 A TW097100936 A TW 097100936A TW 97100936 A TW97100936 A TW 97100936A TW 200845991 A TW200845991 A TW 200845991A
Authority
TW
Taiwan
Prior art keywords
glycine
alkyl
group
hydroxy
dihydro
Prior art date
Application number
TW097100936A
Other languages
English (en)
Chinese (zh)
Inventor
Kevin J Duffy
Antony N Shaw
William Henry Miller
Andrea K Myers
Michael N Zimmerman
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39636631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200845991(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of TW200845991A publication Critical patent/TW200845991A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
TW097100936A 2007-01-12 2008-01-10 N-substituted glycine derivatives: hydroxylase inhibitors TW200845991A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88471007P 2007-01-12 2007-01-12

Publications (1)

Publication Number Publication Date
TW200845991A true TW200845991A (en) 2008-12-01

Family

ID=39636631

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097100936A TW200845991A (en) 2007-01-12 2008-01-10 N-substituted glycine derivatives: hydroxylase inhibitors

Country Status (20)

Country Link
US (2) US7608621B2 (enExample)
EP (2) EP2124565B1 (enExample)
JP (1) JP5313925B2 (enExample)
KR (1) KR101458655B1 (enExample)
CN (1) CN101626685B (enExample)
AR (1) AR064878A1 (enExample)
AU (1) AU2008206441B2 (enExample)
BR (1) BRPI0806566A2 (enExample)
CA (1) CA2675252C (enExample)
CL (1) CL2008000066A1 (enExample)
DK (1) DK2124565T3 (enExample)
EA (1) EA017112B1 (enExample)
ES (2) ES2528745T3 (enExample)
HR (1) HRP20150119T1 (enExample)
MX (1) MX2009007548A (enExample)
PL (1) PL2124565T3 (enExample)
PT (1) PT2124565E (enExample)
SI (1) SI2124565T1 (enExample)
TW (1) TW200845991A (enExample)
WO (1) WO2008089052A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI336260B (en) * 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
SG195607A1 (en) 2005-05-10 2013-12-30 Incyte Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
ITMI20051085A1 (it) * 2005-06-10 2006-12-11 Acs Dobfar Spa Metodo di purificazione del cefotetan
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
MX2009000286A (es) 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
EP2064207B1 (en) * 2006-09-19 2013-11-06 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
US8324405B2 (en) 2008-02-05 2012-12-04 Fibrogen, Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
ES2523720T3 (es) 2008-04-28 2014-12-01 Janssen Pharmaceutica, N.V. Benzoimidazoles como inhibidores de prolilhidroxilasa
NO2824100T3 (enExample) 2008-07-08 2018-07-21
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
EP2326179A4 (en) * 2008-08-25 2011-08-17 Smithkline Beecham Corp PROLYLHYDROXYLASEHEMMER
WO2010055884A1 (ja) * 2008-11-13 2010-05-20 日本農薬株式会社 ピラジン誘導体類の製造方法及びその中間体類
AU2009314155B2 (en) 2008-11-14 2015-10-08 Fibrogen, Inc. Thiochromene derivatives as HIF hydroxylase inhibitors
DE102009004061A1 (de) * 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
PE20120629A1 (es) * 2009-07-17 2012-05-30 Japan Tobacco Inc Compuesto triazolopiridina y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives
PT2492266E (pt) 2009-10-21 2015-11-18 Daiichi Sankyo Co Ltd Derivado de 5-hidroxipirimidino-4-carboxamida
PL2496236T4 (pl) 2009-11-06 2015-11-30 Aerpio Therapeutics Inc Inhibitory hydroksylazy prolilowej
US20130065833A1 (en) * 2010-03-19 2013-03-14 Northwestern University Alkylated sp-b peptoid compounds and related lung surfactant compositions
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (enExample) 2011-06-06 2018-03-17
CA2837560C (en) 2011-06-06 2017-02-14 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
ES2574262T3 (es) 2011-10-25 2016-06-16 Janssen Pharmaceutica, N.V. Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
ES2674813T3 (es) 2012-07-30 2018-07-04 Taisho Pharmaceutical Co., Ltd. Compuesto heterocíclico que contiene nitrógeno parcialmente saturado
PT3007695T (pt) 2013-06-13 2024-03-07 Akebia Therapeutics Inc Composições e métodos para tratamento de anemia
CN109810104B (zh) 2013-11-08 2022-05-03 因赛特控股公司 用于合成吲哚胺2,3-双加氧酶抑制剂的方法
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
US10065928B2 (en) 2014-09-02 2018-09-04 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
CR20170450A (es) 2015-04-01 2018-04-03 Akebia Therapeutics Inc Composiciones y métodos para el tratamiento de la anemia
CN105130888A (zh) * 2015-10-09 2015-12-09 中国药科大学 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途
JP7011830B2 (ja) 2015-10-14 2022-01-27 エックス－サーマ インコーポレイテッド 氷晶形成を低減するための組成物および方法
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021127273A1 (en) * 2019-12-20 2021-06-24 Gb004, Inc. 1 -((6-oxo-1,6-dihydropyridazin-4-yl)methyl)piperazine and 1 -((6-oxo-1,6-dihydropyrimidin-4-yl)methyl)piperazine derivatives as prolyl hydroxylase, hif-1 alpha and pgk modulators for use in treating inflammatory diseases, cancer or infections
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59401923D1 (de) * 1993-11-02 1997-04-10 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
ES2686625T3 (es) 2001-12-06 2018-10-18 Fibrogen, Inc. Métodos para el tratamiento o prevención de la anemia
US6878709B2 (en) * 2002-01-04 2005-04-12 Schering Corporation 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists
US7960398B2 (en) 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US7718624B2 (en) 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
CN101849943A (zh) * 2005-06-06 2010-10-06 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
US7713986B2 (en) 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
BRPI0713836A2 (pt) 2006-07-25 2013-05-28 Cephalon Inc composto, composiÇço farmacÊutica e mÉtodo para tratar distérbio
WO2008040002A2 (en) 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
WO2008073292A2 (en) 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands

Also Published As

Publication number Publication date
WO2008089052A3 (en) 2008-09-18
AR064878A1 (es) 2009-04-29
AU2008206441B2 (en) 2014-06-19
ES2528745T3 (es) 2015-02-12
JP5313925B2 (ja) 2013-10-09
ES2614355T3 (es) 2017-05-30
WO2008089052A2 (en) 2008-07-24
US20080214549A1 (en) 2008-09-04
CA2675252A1 (en) 2008-07-24
EP2124565A4 (en) 2011-06-29
PL2124565T3 (pl) 2015-05-29
SI2124565T1 (sl) 2015-04-30
HRP20150119T1 (hr) 2015-05-08
MX2009007548A (es) 2009-07-22
AU2008206441A1 (en) 2008-07-24
EP2124565A2 (en) 2009-12-02
CN101626685A (zh) 2010-01-13
EP2889289B1 (en) 2016-12-21
US7608621B2 (en) 2009-10-27
PT2124565E (pt) 2015-03-26
DK2124565T3 (en) 2015-02-09
EA200970680A1 (ru) 2010-02-26
JP2010515756A (ja) 2010-05-13
CN101626685B (zh) 2013-03-13
EP2889289A1 (en) 2015-07-01
BRPI0806566A2 (pt) 2014-05-06
USRE44613E1 (en) 2013-11-26
EP2124565B1 (en) 2015-01-07
KR101458655B1 (ko) 2014-11-05
CL2008000066A1 (es) 2008-08-01
KR20090101376A (ko) 2009-09-25
CA2675252C (en) 2015-05-26
EA017112B1 (ru) 2012-09-28

Similar Documents

Publication Publication Date Title
TW200845991A (en) N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) N-substituted glycine derivatives: prolyl hydroxylase inhibitors
TWI394747B (zh) 脯胺醯基羥化酶抑制劑
CA2798622C (en) Indoles
CN101163696B (zh) 组蛋白脱乙酰酶抑制剂
CN104768932B (zh) Pde4的杂芳基抑制剂
TW201311658A (zh) 有益於治療關節炎之新穎咪唑衍生物
TW200936590A (en) P38 inhibitors and methods of use thereof
TW200400033A (en) New pyridazin-3(2H)-one derivatives
TW200808793A (en) Prolyl hydroxylase inhibitors
TW200829591A (en) Organic compounds
WO2009039323A1 (en) Prolyl hydroxylase inhibitors
TW200922583A (en) Certain chemical entities, compositions, and methods
EP2306828A1 (en) Prolyl hydroxylase inhibitors
CA2602250A1 (en) Pyridine derivatives useful as inhibitors of pkc-theta
EP0724572B1 (en) Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands
TW201012800A (en) Substituted 7-sulfanylmethyl-,7-sulfinylmethyl-and 7-sulfonylmethylindoles and the use thereof
US7332485B2 (en) Peptide deformylase inhibitors
CN116924959B (zh) 一种hdac11亚型选择性抑制剂及其制备方法和应用
WO2021129629A1 (zh) Zeste增强子同源物2抑制剂及其用途
WO2010059555A1 (en) Prolyl hydroxylase inhibitors
US6455703B2 (en) 1,3,6,-Trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia
TW201329087A (zh) 胜肽脫甲醯酶抑制劑
HK1107984A1 (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
HK1107984B (en) Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase